65,437 trials
Rotavirus Gastroenteritis
Primary: Geometric Mean Titer of Serum Neutralizing Antibody Response to Human Rotavirus Serotypes G1, G2, G3, G4, and P1A[8] — 99.8; 106.1; 30.0; 26.3 Titer
Recurrent Non-Small Cell Lung Carcinoma · Stage IIIB Non-Small Cell Lung Cancer AJCC v7 · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: 18 Week Progression-free Survival (PFS) Rate — 54; 37; 48 percentage of participants
Ocular Hypertension · Glaucoma
Primary: Incidence of Primary Open-Angle Glaucoma in Hypotensive Patients — 9.5; 4.4; 20.0; 14.1 percent of participants
Breast Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1 — 12; 2; 11; 0 Participants
Chronic Pain
Primary: Pain/Enjoyment of Life/General Activity — -1.24 units on a scale
Lymphoma, B-Cell
Primary: Complete Response (CR) Rate as Assessed by the Investigator at the End of Treatment — 55.0 percentage of participants
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of PD-0332991: Phase 1 — NA; 100 milligram (mg)
Multiple Sclerosis
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 100; 12; 0 Participants
Pain · Back Pain
Primary: Roland and Morris Disability Questionnaire Psychologist-Delivered Treatment Study — 10.0; 10.4; 7.6; 7.8 units on a scale — p=.05
Healthy
Primary: Empagliflozin: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz) — 5990; 5720 nmol*h/L
Pancreatic Cancer · Lymphadenopathy · Gastrointestinal Stromal Tumor
Primary: Diagnostic Yield of EUS-FNB and EUS-FNA — 67.1; 90 percentage of patients
Non-Small Cell Lung Cancer · Dysgeusia · Taste Disorders
Primary: Dysgeusia (UMAMI Perception) — .3; .3 μmol/ml — p=0.013
Healthy
Primary: Safety and Tolerability of N91115 — 9; 6; 6; 6 participants
Attention-deficit/Hyperactivity Disorder
Primary: Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 6 — -17; -25.4; -22.1 units on a scale…
Plaque-type Psoriasis
Primary: Percentage of Participants (Who Achieved a Partial Response Defined as ≥ 50% But < 75% Improvement in Psoriasis Area and Severity Index (PASI) After 12 Weeks of…